Inverted papilloma (IP) is the most common benign neoplasm of the sinonasal tract. With novel endoscopic techniques and an improved understanding of its pathophysiology, IP is now effectively managed through surgery, with recurrence rates as low as 5--10%.^[@B1]^ Standard surgical therapy entails debulking disease until the site of attachment and obtaining an adequate deep margin (including overlying bone, if any).^[@B2]^ Although histologically benign, if left alone, IPs have a propensity to undergo malignant transformation, the rate of which is estimated to be between 5 and 15%.^[@B3]^

Adjunctive therapies, such as radiation and chemotherapy, have traditionally played a limited role in the management of IP and are generally not considered first-line therapy. Indications to consider these therapies generally include multiple recurrences, locally advanced and/or unresectable disease, positive margins, IP with malignant transformation, and poor surgical candidates. Of these tumor characteristics, chemotherapy is truly only considered when there is a suspicion for malignant transformation and, overall, is uncommonly used as a treatment option. We reported a case of a patient with a massive frontal sinus IP with intracranial and orbital extension, initially thought to have malignant disease, with a dramatic response to chemotherapy. This report was approved by the institutional review board of the University of California, Los Angeles, California.

CASE PRESENTATION
=================

A 75-year-old healthy male patient presented to the clinic at a tertiary cancer center with nasal obstruction, purulent nasal discharge, and a growing left supra- and intraorbital mass over the past 7 months. There was an associated 15-lb (6.8-kg) weight loss. He had a nasal biopsy performed outside of the hospital, which was read as IP with squamous cell carcinoma *in situ*. Nasal endoscopy revealed a large polypoid nasal mass that filled both the frontal and ethmoid sinuses, with apparent left orbital invasion. Computed tomography ([Fig. 1](#F1){ref-type="fig"}) and magnetic resonance imaging ([Fig. 2](#F2){ref-type="fig"}) of the sinuses was obtained and showed the mass extending posteriorly within the frontal sinus, with associated mucocele formation, which eroded the posterior table over an area of 1.73 × 1.40 cm. Of note, the patient had a 60 pack-year smoking history and consumed six alcoholic drinks per week over the past 30 years.

![Pretreatment computed tomography of the sinuses demonstrates extensive disease filling the frontal and ethmoid sinuses, with mucocele formation, leading to left intraorbital extension and erosion of the posterior table of the frontal sinus.](arh0021702010001){#F1}

![Pretreatment magnetic resonance imaging of the sinuses once again demonstrates the extensive left-sided disease with associated mucocele.](arh0021702010002){#F2}

He was initially deemed by the treating team to have unresectable disease, with the large mass being unable to be selectively encompassed by radiation therapy. As such, he elected chemotherapy with carboplatin (306.3 mg per cycle) and paclitaxel (542.4 mg per cycle), which he completed over 6 weeks (four cycles). As treatment progressed, although he had adverse effects from the chemotherapy, his sinonasal symptoms improved and his left supraorbital swelling began to regress ([Fig. 3](#F3){ref-type="fig"}).

![Before (left), during (6 weeks after initiation of therapy) (center), and after (2 months after completion of therapy) (right) chemotherapy pictures of the patient (used with written permission), with near-complete resolution of the left supraorbital swelling.](arh0021702010003){#F3}

He was then referred to a tertiary rhinology clinic, where he elected for definitive surgical management to remove any residual disease. A repeated preoperative computed tomography demonstrated marked shrinkage of the mass ([Fig. 4](#F4){ref-type="fig"}). An endoscopic modified Lothrop procedure (Draf III) was performed, during which only a small focus of IP was found along the superior wall of the left frontal sinus ([Fig. 5](#F5){ref-type="fig"}). Of note, there was a large area of posterior table erosion, with dural pulsations visible through the mucosa and no intervening bony layer, although there was no frank intracranial connection. The final pathology results showed only IP without squamous cell carcinoma *in situ* or dysplasia. The patient had been followed up every 1--2 months as an outpatient and remained recurrence free at 1 year after surgery, with good overall functional status after recovery from chemotherapy.

![Postchemotherapy computed tomography of the sinuses demonstrates near resolution of the left frontal sinus mass; areas of supraorbital and posterior table dehiscence are evident.](arh0021702010004){#F4}

![Postoperative endoscopy of the Draf III cavity demonstrated mucosal healing but no evidence of recurrent disease, with a visible dehiscence of the posterior table of the frontal sinus.](arh0021702010005){#F5}

DISCUSSION
==========

Most IP cases can be effectively treated, even cured, by endoscopic sinus surgery alone. In contrast, previous reports indicate that squamous cell carcinoma that arises from IP has a guarded prognosis, of 63% survival at 3 years.^[@B4]^ This particular patient was treated with chemotherapy because the initial biopsy result was suggestive of malignant transformation. Incidentally, it achieved a "medical debulking" phenomenon, which facilitated his subsequent surgery (*e.g.*, decreased disease burden, decreased blood loss, improved access). Although extremely rare for patients with IP in difficult-to-access areas (*e.g.*, lateral frontal sinus), extensive disease, or malignant transformation, neoadjuvant systemic chemotherapy may improve surgical access, which allowed for a chance of a cure. There is at least some interest in identifying novel chemotherapeutic agents for the management of IP, with photodynamic therapy showing some efficacy.^[@B5]^ Adriaensen *et al.*^[@B6]^ suggested efficacy in topical application of 5-fluorouracil, a nucleoside synthesis inhibitor, over sites where complete mucoperiosteum and bone removal may not be possible. It is critical to weigh the risks and benefits of chemotherapy with the patient before deciding on treatment. In this case, carboplatin, an alkylating agent, is associated with myelosuppression and thus an elevated risk of opportunistic infections, whereas paclitaxel, a tubulin-targeting drug, is frequently associated with peripheral neuropathy. Both drugs may also cause systemic toxicity, such as nausea and vomiting, hair loss, and diarrhea.

As we begin to understand more about the pathophysiology of IP, surgical strategies have evolved to address this disease process. Specifically, once the tumor has been debulked and the site of attachment is identified, removal of this site, followed by drilling, cauterization, or excision of the underlying bone is now considered standard of care.^[@B2]^ Primary cases have a higher rate of cure because revision cases are often associated with distorted anatomic landmarks, multiple sites of attachments, and tumor seeding.^[@B7]^ IPs with sites of attachments in the frontal and sphenoid sinuses pose special challenges due to the proximity of the skull base. For frontal sinus IPs, medial and posterior wall IPs may often be completely removed *via* a standard unilateral endoscopic frontal sinusotomy, whereas those with broader attachments or multifocal involvement may be best accessed *via* a modified endoscopic Lothrop procedure. For extremely extensive frontal sinus IPs, a frontal sinus trephination or osteoplastic flap procedure may be indicated for complete removal of disease. However, the posterolateral wall of the sphenoid sinus houses the optic nerve and carotid arteries, and complete bone removal overlying these structures is infeasible. For this reason, sphenoid sinus IP has a high rate of recurrence (14.6%),^[@B8]^ and, oftentimes, the decision is made to perform a subtotal resection with judicious follow up and surveillance as opposed to risk injury to the underlying neurovascular structures.

Similar to but more spatially selective than chemotherapy is the potential value of radiation therapy in treating IPs. In contrast to chemotherapy, radiation allows for selective targeting of primary tumor sites, although local toxicity to surrounding normal structures must be taken into consideration before treatment. This is especially true with the advent of newer technologies, such as intensity modulation or stereotactic guidance, in which concentrated radiation doses may be delivered to a targeted area with precision and spatial selectivity. For instance, Hug *et al.*^[@B9]^ reported that 7 of 7 patients (100%) with IP and 15 of 18 of patients with IP and with associated invasive carcinoma (83%) achieved long-term recurrence-free survival after primary or adjuvant radiation therapy. There are other reports with similar results, with good local control rates.^[@B10]^ However, the unifying theme of advocating for the use of radiation therapy is only in the context of failed surgical management, especially in patients with unresectable, multiply recurrent, or malignant disease.

CONCLUSION
==========

Although not without its comorbidities and medical and functional sequelae, chemotherapy may be considered in rare cases of unresectable IP. We reported, to our knowledge, the first case in the literature of a patient who, after receiving treatment, has performed remarkably well and remained free of recurrent disease today.
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